Jordan News

MS Pharma, a leading regional pharmaceutical company, announced the signing of an exclusive agreement with mAbxience to market the biosimilar Bevacizumab in the Middle East and North Africa, for the treatment of some types of cancer.
MS Pharma said in a press release today, Tuesday, that the biosimilar “bevacizumab” has recently been approved by the European Medicines Agency, and treats some types of cancer, such as colon or rectal cancer, breast cancer, lung cancer, renal cell cancer, and ovarian cancer. epithelial ovary, fallopian tube or primary peritoneal cancer, and cervical cancer, and will be available as an injectable solution.
Headquartered in Amman, the regional company aims to provide patients across the Middle East and North Africa region with access to high-quality, affordable bio-replacement and oncology therapies for the region.